Clinical Trials Browser

Has results × Lymphoma, B-Cell × Alemtuzumab × Clear all

NCT01030900 2022-10-06

Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

Phase 2 Completed

50 enrolled 13 charts

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse